CA_logo-blueCaring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

February 2012

 

 

Clinical Trials, Cohort Studies, Pilot Studies

 

Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.

Pessôa MG, Cheinquer H, Almeida PR, et al. Ann Hepatol. 2012 Jan-Feb;11(1):52-61.

http://www.ncbi.nlm.nih.gov/pubmed/22166561

 

Predictors of Changes in Hemoglobin Levels in Patients with Chronic Hepatitis C Treated with Ribavirin Plus Pegylated Interferon-α Hu CC, Weng CH, Lin CL, et al. Ren Fail. 2012 Jan 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22264026

 

Impact of IL28B-Related Single Nucleotide Polymorphisms on Liver Histopathology in Chronic Hepatitis C Genotype 2 and 3. Rembeck K, Alsiö A, Christensen PB, et al. PLoS One. 2012;7(1):e29370. Epub 2012 Jan 13.

http://www.ncbi.nlm.nih.gov/pubmed/22253715

 

Type 2 diabetes mellitus and chronic hepatitis C: Which is worse? Results of a long-term retrospective cohort study. Giordanino C, Ceretto S, Bo S, Smedile A, et al.  Dig Liver Dis. 2012 Jan 13. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22245505

 

Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Nelson DR, Zeuzem S, Andreone P, et al. Ann Hepatol. 2012 Jan-Feb;11(1):15-31.

http://www.ncbi.nlm.nih.gov/pubmed/22166557

 

Ribavirin dose and treatment outcome of Korean patients with genotype 1 chronic hepatitis C. Sinn DH, Kim J, Shin SR, et al. Hepatogastroenterology. 2012 Jan-Feb;59(113):1-6. doi: 10.5754/hge11387.

http://www.ncbi.nlm.nih.gov/pubmed/21940368

 

Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin. Namikawa M, Kakizaki S, Yata Y, et al. J Gastroenterol Hepatol. 2012 Jan;27(1):69-75. doi: 10.1111/j.1440-1746.2011.06802.x.

http://www.ncbi.nlm.nih.gov/pubmed/21649727

 

 

 

 

Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b. Toyoda H, Kumada T, Tada T, et al. J Med Virol. 2012 Jan;84(1):61-70. doi: 10.1002/jmv.22272.

http://www.ncbi.nlm.nih.gov/pubmed/22095536

 

Preliminary study of two antiviral agents for hepatitis C genotype 1. Lok AS, Gardiner DF, Lawitz E, et al. N Engl J Med. 2012 Jan 19;366(3):216-24.

http://www.ncbi.nlm.nih.gov/pubmed/22256805

 

Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis C and pretreatment low platelet counts. Lin KH, Hsu PI, Yu HC, et al. BMC Gastroenterol. 2012 Jan 18;12(1):7. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22257364

 

Developing a Modified Directly Observed Therapy Intervention for Hepatitis C Treatment in a Methadone Maintenance Program: Implications for Program Replication. Bruce RD, Eiserman J, Acosta A, Gote C, Lim JK, Altice FL. Am J Drug Alcohol Abuse. 2012 Jan 13. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22242700

 

Basic and Applied Science, Pre-Clinical Studies

 

HCV Infection Induces a Unique Hepatic Innate Immune Response Associated with Robust Production of Type III Interferons. Thomas E, Gonzalez VD, Li Q, et al. Gastroenterology. 2012 Jan 13. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22248663

 

Inhibition of hepcidin transcription by growth factors. Goodnough JB, Ramos E, Nemeth E, Ganz T. Hepatology. 2012 Jan 25. doi: 10.1002/hep.25615. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22278715

 

Hepatitis C Virus Infection of Human T Lymphocytes is Mediated by CD5. Sarhan MA, Pham TN, Chen AY, Michalak TI. J Virol. 2012 Jan 25. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22278227

 

Development of persistent HCV genotype 3a infection cell culture model in huh-7 cell.

Asad S, Ijaz B, Ahmad W, Kausar H, et al. Virol J. 2012 Jan 10;9(1):11. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22234052

 

ENT1, a ribavirin transporter, plays a pivotal role in antiviral efficacy of ribavirin in a hepatitis C virus replication cell system. Iikura M, Furihata T, Mizuguchi M, et al. Antimicrob Agents Chemother. 2012 Jan 9. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22232287

 

Effect of IL28B Genotype on Early Viral Kinetics during Interferon-Free Treatment of Patients with Chronic Hepatitis C. Chu TW, Kulkarni R, Gane EJ, et al. Gastroenterology. 2012 Jan 13. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22248659

 

Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Liu L, Fisher BE, Thomas DL, Cox AL, Ray SC. Hepatology. 2012 Jan 11. doi: 10.1002/hep.25575. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22234804

 

 

Permissiveness of human hepatoma cell lines for HCV infection. Sainz B Jr, Barretto N, Yu X, Corcoran P, Uprichard SL. Virol J. 2012 Jan 24;9(1):30. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22273112

 

HIV/HCV Coinfection

 

Lack of short-term increase in serum mediators of fibrogenesis and in non-invasive markers of liver fibrosis in HIV/hepatitis C virus-coinfected patients starting maraviroc-based antiretroviral therapy. Macías J, Viloria MM, Rivero A, et al. Eur J Clin Microbiol Infect Dis. 2012 Jan 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22258426

 

Hepatitis C virus infection is associated with painful symptoms in HIV-infected adults.

Tsui JI, Cheng DM, Libman H, Bridden C, Samet J. AIDS Care. 2012 Jan 24. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22272656

 

Influence of IL28B Polymorphisms on Response to a Lower-Than-Standard Dose peg-IFN-α 2a for Genotype 3 Chronic Hepatitis C in HIV-Coinfected Patients. López-Cortés LF, Ruiz-Valderas R, Jimenez-Jimenez L, et al. PLoS One. 2012;7(1):e28115. Epub 2012 Jan 3.

http://www.ncbi.nlm.nih.gov/pubmed/22235243

 

Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis c virus-coinfected liver transplant recipients: A FIPSE/GESIDA Prospective Cohort Study.

Moreno A, Cervera C, Fortún J, et al. Liver Transpl. 2012 Jan;18(1):70-81. doi: 10.1002/lt.22431.

http://www.ncbi.nlm.nih.gov/pubmed/21898772

 

Impact of hepatitis C viral clearance on CD4+ T-lymphocyte course in HIV/HCV coinfected patients treated with pegylated interferon plus ribavirin. Milazzo L, Foschi A, Mazzali C, et al. AIDS Res Hum Retroviruses. 2012 Jan 5. [Epub ahead of print]

Viola A, Ridolfo A, Galli M, Antinori S.

http://www.ncbi.nlm.nih.gov/pubmed/22220723

 

HCV coinfection does not alter the frequency of regulatory T cells or CD8+ T cell immune activation in chronically infected HIV+ Chinese subjects. Zhuang Y, Wei X, Li Y, Zhao K, Zhang J, Kang W, Sun Y. AIDS Res Hum Retroviruses. 2012 Jan 4. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22214236

 

Hepatitis C virus co-infection and sexual risk behaviour are associated with a high homocysteine serum level in HIV-infected patients. Roca B, Bennasar M, Ferrero JA, Del Monte MC, Resino E. Swiss Med Wkly. 2012 Jan 11;141:w13323. doi: 10.4414/smw.2011.13323.

http://www.ncbi.nlm.nih.gov/pubmed/22252925

 

Change in Fibrosis Score as a Predictor of Mortality Among HIV-Infected Patients with Viral Hepatitis. Jain MK, Seremba E, Bhore R, et al. AIDS Patient Care STDS. 2012 Jan 12. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22239101

 

Epidemiology, Diagnostics, and Miscellaneous Works

 

A Tetra-Primer Amplification Refractory Mutation System-Polymerase Chain Reaction for the Detection of rs8099917 IL28B Genotype. Hashemi M, Moazeni-Roodi A, Bahari A, Taheri M. Nucleosides Nucleotides Nucleic Acids. 2012 Jan;31(1):55-60.

http://www.ncbi.nlm.nih.gov/pubmed/22257210

 

Sequence Analysis of the IL28A/IL28B Inverted Gene Duplication That Contains Polymorphisms Associated with Treatment Response in Hepatitis C Patients. Reynolds JM, Paciga SA, Sanders FA, Hyde CL, Loomis AK, Johnston GI. PLoS One. 2012;7(1):e29983. Epub 2012 Jan 10.

http://www.ncbi.nlm.nih.gov/pubmed/22253847

 

Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Boursier J, de Ledinghen V, Zarski JP, et al. Hepatology. 2012 Jan;55(1):58-67. doi: 10.1002/hep.24654.

http://www.ncbi.nlm.nih.gov/pubmed/21898504

 

Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Torres HA, Davila M. Nat Rev Clin Oncol. 2012 Jan 24. doi: 10.1038/nrclinonc.2012.1. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22271089

Infections with hepatitis B virus (HBV) or hepatitis C virus (HCV) are associated with

A morphometric and immunohistochemical study to assess the benefit of an SVR in HCV cirrhotic patients. D'Ambrosio R, Aghemo A, Grazia Rumi M, et al. Hepatology. 2012 Jan 23. doi: 10.1002/hep.25606. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22271347

 

 

Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. Hsu PC, Federico CA, Krajden M, et al. J Gastroenterol Hepatol. 2012 Jan;27(1):149-157. doi: 10.1111/j.1440-1746.2011.06813.x.

http://www.ncbi.nlm.nih.gov/pubmed/21679248

 

The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Bruneau J, Roy E, Arruda N, Zang G, Jutras-Aswad D. Addiction. 2012 Jan 16. doi: 10.1111/j.1360-0443.2012.03803.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22248184

 

Liver Cancer

 

Circulating Transforming Growth Factor-β and Epidermal Growth Factor Receptor as Related to Virus Infection in Liver Carcinogenesis. Divella R, Daniele A, Gadaleta C, et al. Anticancer Res. 2012 Jan;32(1):141-5.

http://www.ncbi.nlm.nih.gov/pubmed/22213299

 

Value of alpha-foetoprotein for screening of recurrence in hepatocellular carcinoma post resection. Chang SK, Hlaing WW, Yu RQ, Lee TW, Ganpathi IS, Madhavan KK. Singapore Med J. 2012 Jan;53(1):32-5.

http://www.ncbi.nlm.nih.gov/pubmed/22252180

 

Effect of interferon therapy on first and second recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Sakae M, Kubo S, Takemura S, et al. Hepatol Res. 2012 Jan 18. doi: 10.1111/j.1872-034X.2011.00959.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22257119

 

Resection of Hepatocellular Carcinoma Without Cirrhosis. Shrager BJ, Jibara G, Schwartz M, Roayaie S. Ann Surg. 2012 Jan 17. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22258064

 

Molecular epidemiology in HCV-related hepatocellular carcinoma: first steps. Villanueva A, Forns X, Llovet JM. J Hepatol. 2012 Jan 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22282033